arrow
S

Shirley D'Sa

university college london
H指数:36
被引数:5,189

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up

奥加曲沙在瓦尔登斯特伦巨球蛋白血症中,5年随访显示持久应答

2026-04-170
OAAI
Zanubrutinib in AL Amyloidosis Associated With Waldenström Macroglobulinemia and Other B-Cell Non-Hodgkin Lymphoma

泽鲁布替尼在与华氏巨球蛋白血症及其他B细胞非霍奇金淋巴瘤相关的AL淀粉样变性中的应用

2026-03-160
OAAI
POD24 is a Novel Determinant of Prognosis in Patients with Waldenström Macroglobulinemia

POD24是沃尔德斯特伦巨球蛋白血症患者预后的新型决定因素。

2026-01-090
OAAI
Report of Consensus Panel 1 from the 12th International Workshop on the management of patients with IgM and Waldenstrom's Macroglobulinemia related neuropathy

第十二届关于IgM及华氏巨球蛋白血症相关神经病变患者管理国际研讨会共识专家组1的报告

2025-05-020
PRE
Real World Treatment Outcomes in the First Line Management of Waldenström Macroglobulinemia from the Global Patient Derived Data Registry, Whimsical

真实世界下Waldenström巨球蛋白血症一线治疗管理的结果:来自全球患者衍生数据登记库Whimsical的数据

BLOOD
IF23.1
2024-11-050
PRE
Long-term efficacy and safety of continued complement C1s inhibition with sutimlimab in cold agglutinin disease: CADENZA study Part B
2024-08-010
OAAI
Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia
2024-03-283
OAAI
Long-term outcomes by bone marrow B-cell depletion from the R2W trial of bortezomib with cyclophosphamide and rituximab in Waldenstrőm macroglobulinaemia

硼替佐米联合环磷酰胺和利妥昔单抗治疗waldenstr ő m巨球蛋白血症的R2W试验中骨髓b细胞耗竭的长期结果

LEUKEMIA
IF13.4
2024-02-261
OA
SARS-CoV-2 Infection in Patients With Waldenstrom's Macroglobulinemia: A Multicenter International Cohort Study
2023-06-011
OAAI